4 recruiting, 3 active not recruiting, 1 completed, 1 not yet recruiting. 9 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Recruiting 4, Active not recruiting 3, Completed 1, Not yet recruiting 1 |
| Phase 2 | 3 | Recruiting 3 |
Follow inavolisib: new trials by email Literature Review of inavolisib trials Research Report on inavolisib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral GDC-0077 in Premature Ovarian Insufficiency GDC-0077 - Primary Ovarian Insufficiency | Phase 1 | Not yet recruiting | Women's Hospital School Of Medicine Zhejiang University | 12 | 2026-10-30 | 2026-10-29 |
| A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib Inavolisib - Hepatic Impairment | Phase 1 | Completed | Genentech, Inc. | 27 | 2025-08-21 | 2026-10-23 |
| A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers Inavolisib, Atezolizumab - PIK3CA-Mutated Cancers | Phase 1 | Active not recruiting | Hoffmann-La Roche | 30 | 2023-12-11 | 2026-11-13 |
| A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) Inavolisib, Bevacizumab, Cetuximab - Metastatic Colorectal Cancer | Phase 1 | Recruiting | Hoffmann-La Roche | 542 | 2021-10-22 | 2026-11-06 |
| A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer Atezolizumab - 28 Day Cycle, Bevacizumab, Ipatasertib - Endometrial Cancer | Phase 1 / Phase 2 | Recruiting | Alliance Foundation Trials, LLC. | 148 | 2021-10-20 | 2026-04-01 |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer Giredestrant, Abemaciclib, Ipatasertib - Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer | Phase 1 / Phase 2 | Recruiting | Hoffmann-La Roche | 316 | 2021-06-22 | 2026-11-03 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation GDC-6036, Atezolizumab, Cetuximab - Non-Small Cell Lung Cancer, Colorectal Cancer | Phase 1 | Active not recruiting | Genentech, Inc. | 498 | 2020-07-29 | 2026-08-28 |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer Capecitabine, Atezolizumab, Ipatasertib - Metastatic Breast Cancer | Phase 1 / Phase 2 | Recruiting | Hoffmann-La Roche | 1132 | 2018-03-30 | 2026-11-06 |
| To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer Inavolisib, Fulvestrant, Letrozole - Breast Cancer, Solid Tumor | Phase 1 | Active not recruiting | Genentech, Inc. | 200 | 2016-12-13 | 2026-09-08 |
Breast Neoplasms (2) · Colorectal Neoplasms (2) · Neoplasm Metastasis (2) · Carcinoma, Non-Small-Cell Lung (1) · Endometrial Neoplasms (1) · Primary Ovarian Insufficiency (1)
Hoffmann-La Roche (4) · Genentech, Inc. (3) · Alliance Foundation Trials, LLC. (1) · Women's Hospital School Of Medicine Zhejiang University (1)
United States (8) · South Korea (5) · Spain (5) · Australia (4) · Canada (4) · United Kingdom (4) · Israel (3) · France (2) · Germany (2) · Italy (2) · Poland (2) · Taiwan (2) · Belgium (1) · Brazil (1) · Denmark (1)
PMID 37611121, PMID 38052910, PMID 39236276, PMID 40632992, PMID 40896848
2023 (5), 2016 (1), 2017 (1)